Dendritic Cell Immunotherapy — CPB 0377 | AETNA Coverage Update

Aetna modified CPB 0377 covering dendritic cell immunotherapy, effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0377 governing dendritic cell immunotherapy coverage. This modification applies to a broad range of malignant neoplasms — spanning ICD-10 ranges C00.0–C43.9, C44.00–C75.9, C76.0–C86.61, C88.40–C94.32, and C94.80–C96.4, plus individual codes C96.6, C96.7, C96.8, and C96.9 — as well as melanoma in situ codes D03.0 through D03.9. If your practice bills for oncology treatments or supports a cancer center, this coverage policy change deserves immediate attention.

Quick-Reference Table

Aetna Dendritic Cell Immunotherapy Coverage Criteria and Medical Necessity Requirements 2025

Dendritic cell immunotherapy is a category of cancer treatment that uses a patient's own immune cells — trained to recognize tumor antigens — to attack cancer cells. Aetna's coverage policy under CPB 0377 applies this framework across virtually every major malignancy category.

The ICD-10 codes covered under this policy span nearly the entire malignant neoplasm chapter. Ranges C00.0–C43.9, C44.00–C75.9, C76.0–C86.61, C88.40–C94.32, and C94.80–C96.4, plus individual codes C96.6, C96.7, C96.8, and C96.9, cover leukemia, lymphoma, melanoma, and solid tumors. Melanoma in situ (D03.0–D03.9) is also listed, which signals that Aetna is drawing a wide perimeter around the diagnoses where this policy applies.

The breadth of diagnosis codes here is notable. This is not a narrow oncology policy limited to one tumor type or one line of therapy. Your billing team should treat any dendritic cell immunotherapy claim for an oncology patient as potentially subject to CPB 0377 review.

Medical necessity documentation is going to be the center of every claim dispute here. If you're not sure how your documentation maps to Aetna's current standards, talk to your compliance officer before the effective date of September 26, 2025.

Prior authorization requirements are not specified in CPB 0377 source data. Confirm whether prior auth applies to your specific plan contract directly with Aetna before submission. When submitting clinical documentation, address medical necessity directly — tumor type, stage, prior treatment history, and the rationale for choosing a dendritic cell approach over alternatives.

Reimbursement for these therapies is not straightforward. Dendritic cell immunotherapy sits at the intersection of lab, infusion, and oncology billing — and each component may bill differently. Understand which codes your facility uses for the preparation, processing, and administration of these treatments before you touch a claim.

Aetna Dendritic Cell Immunotherapy Exclusions and Non-Covered Indications

The policy data does not include a separate list of explicitly non-covered CPT or HCPCS codes. But that doesn't mean there are no exclusions.

The real issue here is that the ICD-10 code list in this policy is expansive, but a broad diagnosis list does not mean broad coverage. Aetna's reviewers will still apply medical necessity criteria at the claim level. Having a covered ICD-10 code does not guarantee payment — it means the diagnosis falls within the scope of the policy. The coverage determination still depends on the specific therapy, its FDA status, and the supporting clinical documentation.

If your practice is billing dendritic cell immunotherapy using an investigational protocol, flag those claims for your compliance officer before submission. The risk of claim denial in this category is high.

Coverage Indications at a Glance

Aetna Dendritic Cell Immunotherapy Billing Guidelines and Action Items 2025

The effective date of September 26, 2025 is your deadline for getting claims and processes aligned with the updated CPB 0377. Here's what to do now.

CPT, HCPCS, and ICD-10 Codes for Dendritic Cell Immunotherapy Under CPB 0377

The policy data for CPB 0377 does not list specific CPT or HCPCS codes. Dendritic cell immunotherapy billing guidelines often require facility- or therapy-specific code selection depending on the product, administration method, and payer contract. Work with your coding team to confirm the correct procedure codes for each therapy type — and verify those codes against Aetna's current fee schedule and any applicable local coverage determination rules.

Key ICD-10-CM Diagnosis Codes

A note on CPT and HCPCS: the absence of specific procedure codes in the published CPB 0377 data is itself a billing signal. It means Aetna's coverage determination is diagnosis- and therapy-driven — not code-driven. The procedure code you choose still matters for reimbursement, but the coverage decision starts with whether the therapy and diagnosis combination meets medical necessity criteria under the policy. Your coding team should document their code selection rationale in the claim file.